TITLE:
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

CONDITION:
Diabetes Mellitus, Non-Insulin-Dependent

INTERVENTION:
naveglitazar

SUMMARY:

      The purpose of this study is to determine if an investigational drug is safe and efficacious
      for poorly controlled type 2 diabetes mellitus.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 70 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of Type 2 Diabetes for at least 3 months.

          -  Diabetes managed with diet and exercise alone or with either metformin or
             sulfonylurea alone as an adjunct to diet and exercise.

          -  Diabetes therapy must be unchanged for at least 3 months prior to screening.

          -  Females must be of non-childbearing potential (surgically sterilized or at least 1
             year post-menopausal, as defined by cessation of menses). Female patients who are not
             surgically sterilized and who are less than or equal to 45 years should have their
             post-menopausal status confirmed by FSH greater that 30ng/mL at screening.

        Exclusion Criteria:

          -  Current use of insulin or any antidiabetic agent other than a sulfonylurea agent or
             metformin.

          -  Current use of metformin or a sulfonylurea agent in combination.

          -  History of liver disease.

          -  History of unstable angina (as defined by the Braunwald system), myocardial
             infarction, or a coronary revascularization procedure within the past 6 months.

          -  Currently suspected carcinoma or history of carcinoma in the last 5 years, with the
             exception of excised superficial lesions such as basal cell carcinoma and squamous
             cell carcinoma of the skin.
      
